240 related articles for article (PubMed ID: 37490552)
1. Targeting Squalene Epoxidase Confers Metabolic Vulnerability and Overcomes Chemoresistance in HNSCC.
Zhao X; Guo B; Sun W; Yu J; Cui L
Adv Sci (Weinh); 2023 Sep; 10(27):e2206878. PubMed ID: 37490552
[TBL] [Abstract][Full Text] [Related]
2. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
Cui L; Lu Y; Zheng J; Guo B; Zhao X
J Exp Clin Cancer Res; 2023 Dec; 42(1):335. PubMed ID: 38057867
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of SQLE Contributes to Poor Survival in Head and Neck Squamous Cell Carcinoma.
Li J; Yang T; Wang Q; Li Y; Wu H; Zhang M; Qi H; Zhang H; Li J
Int J Biol Sci; 2022; 18(9):3576-3591. PubMed ID: 35813482
[TBL] [Abstract][Full Text] [Related]
4. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Squalene Epoxidase by Cholesterol Accumulation Accelerates Colorectal Cancer Progression and Metastasis.
Jun SY; Brown AJ; Chua NK; Yoon JY; Lee JJ; Yang JO; Jang I; Jeon SJ; Choi TI; Kim CH; Kim NS
Gastroenterology; 2021 Mar; 160(4):1194-1207.e28. PubMed ID: 32946903
[TBL] [Abstract][Full Text] [Related]
6. Squalene epoxidase promotes the chemoresistance of colorectal cancer via (S)-2,3-epoxysqualene-activated NF-κB.
Liu Q; Zhang Y; Li H; Gao H; Zhou Y; Luo D; Shan Z; Yang Y; Weng J; Li Q; Yang W; Li X
Cell Commun Signal; 2024 May; 22(1):278. PubMed ID: 38762737
[TBL] [Abstract][Full Text] [Related]
7. Squalene epoxidase/SQLE is a candidate target for treatment of colorectal cancers with
Du Y; Rokavec M; Hermeking H
Int J Biol Sci; 2023; 19(13):4103-4122. PubMed ID: 37705742
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of squalene epoxidase linking with PI3K/AKT signaling pathway suppresses endometrial cancer.
Ma L; Huang W; Liang X; Bai G; Wang X; Jiang H; Xin Y; Hu L; Chen X; Liu C
Cancer Sci; 2023 Sep; 114(9):3595-3607. PubMed ID: 37438885
[TBL] [Abstract][Full Text] [Related]
9. Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.
Liu D; Wong CC; Zhou Y; Li C; Chen H; Ji F; Go MYY; Wang F; Su H; Wei H; Cai Z; Wong N; Wong VWS; Yu J
Gastroenterology; 2021 Jun; 160(7):2467-2482.e3. PubMed ID: 33647280
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.
Liu S; Qin Z; Mao Y; Wang N; Zhang W; Wang Y; Chen Y; Jia L; Peng X
Theranostics; 2024; 14(2):622-639. PubMed ID: 38169606
[No Abstract] [Full Text] [Related]
11. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway.
Xu R; Song J; Ruze R; Chen Y; Yin X; Wang C; Zhao Y
Cell Death Dis; 2023 Aug; 14(8):497. PubMed ID: 37542052
[TBL] [Abstract][Full Text] [Related]
12. Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer.
Shangguan X; Ma Z; Yu M; Ding J; Xue W; Qi J
Cancer Res; 2022 Sep; 82(17):3032-3044. PubMed ID: 35767703
[TBL] [Abstract][Full Text] [Related]
13. Squalene epoxidase-induced cholesteryl ester accumulation promotes nasopharyngeal carcinoma development by activating PI3K/AKT signaling.
Li L; Zhang Q; Wang X; Li Y; Xie H; Chen X
Cancer Sci; 2020 Jul; 111(7):2275-2283. PubMed ID: 32314495
[TBL] [Abstract][Full Text] [Related]
14. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
16. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.
Liu D; Wong CC; Fu L; Chen H; Zhao L; Li C; Zhou Y; Zhang Y; Xu W; Yang Y; Wu B; Cheng G; Lai PB; Wong N; Sung JJY; Yu J
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669855
[TBL] [Abstract][Full Text] [Related]
17. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
18. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis.
Li C; Wang Y; Liu D; Wong CC; Coker OO; Zhang X; Liu C; Zhou Y; Liu Y; Kang W; To KF; Sung JJ; Yu J
Gut; 2022 Nov; 71(11):2253-2265. PubMed ID: 35232776
[TBL] [Abstract][Full Text] [Related]
19. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
20. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
